RenovoRx Inc expected to post a loss of 10 cents a share - Earnings Preview

RenovoRx

28/03/2025 20:24

RenovoRx Inc RNXT.OQ RNXT.O is expected to show no change in quarterly revenue when it reports  results on April 1 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for RenovoRx Inc is for a loss of 10 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for RenovoRx Inc is $4.00​, above​ its last closing price of $1.02. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.12
-0.12
-0.10
Beat
16.7
Jun. 30 2024
-0.10
-0.10
-0.10
Met
0
Mar. 31 2024
-0.13
-0.14
-0.07
Beat
51.7​
Dec. 31 2023
-0.30
-0.30
-0.31
Missed
-2.2
​​Sep. 30 2023
-0.30
-0.30
-0.13
Beat
56.7
Jun. 30 2023
-0.25
-0.25
-0.31
Missed
-24​
Mar. 31 2023
-0.25
-0.25
-0.36
Missed
-44
Dec. 31 2022
-0.26
-0.26
-0.23
Beat
11.5

This summary was machine generated March 28 at 20:24 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)